Hasil Pencarian - Andrea Pirzkall

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    USE OF PROTON MAGNETIC RESONANCE SPECTROSCOPIC IMAGING DATA IN PLANNING FOCAL RADIATION THERAPIES FOR BRAIN TUMORS

    USE OF PROTON MAGNETIC RESONANCE SPECTROSCOPIC IMAGING DATA IN PLANNING FOCAL RADIATION THERAPIES FOR BRAIN TUMORS oleh Edward E Graves, Andrea Pirzkall, Tracy R Mcknight, Daniel B Vigneron, David A Larson, Lynn J Verhey, Michael Mcdermott, Susan Chang, Sarah J Nelson

    Diterbitkan 2011-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors

    753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors oleh Costantine Albany, Andrea Pirzkall, Michael Chisamore, Jennifer Visich, Elizabeth I Buchbinder, Xiaohan Liu, David R Spigel, Kelly D Moynihan, Christopher DelNagro, Matt Axt, Mark Sayles

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors

    507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced s... oleh Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Andrea Pirzkall, Praveen Bommareddy, Isla Leslie, Francesca Aroldi, Pablo Nenclares, Tze Chan, Imran Saleem, Henry Castro

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Molecular biomarker analyses using circulating tumor cells.

    Molecular biomarker analyses using circulating tumor cells. oleh Elizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, Heidi Savage, Ajay Pandita, Ru-Fang Yeh, Andrea Pirzkall, Bernard M Fine, Lukas C Amler, Daniel S Chen, Mark R Lackner

    Diterbitkan 2010-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

    High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. oleh David S Shames, Juliet Carbon, Kim Walter, Adrian M Jubb, Cleopatra Kozlowski, Tom Januario, An Do, Ling Fu, Yuanyuan Xiao, Rajiv Raja, Brittany Jiang, Ashi Malekafzali, Howard Stern, Jeff Settleman, Timothy R Wilson, Garret M Hampton, Robert L Yauch, Andrea Pirzkall, Lukas C Amler

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

    Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study) oleh Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken

    Diterbitkan 2016-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

    Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck oleh David S. Shames, Juliet Carbon, Kim Walter, Adrian M. Jubb, Cleopatra Kozlowski, Tom Januario, An Do, Ling Fu, Yuanyuan Xiao, Rajiv Raja, Brittany Jiang, Ashi Malekafzali, Howard Stern, Jeff Settleman, Timothy R. Wilson, Garret M. Hampton, Robert L. Yauch, Andrea Pirzkall, Lukas C. Amler

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck.

    Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck. oleh David S. Shames, Juliet Carbon, Kim Walter, Adrian M. Jubb, Cleopatra Kozlowski, Tom Januario, An Do, Ling Fu, Yuanyuan Xiao, Rajiv Raja, Brittany Jiang, Ashi Malekafzali, Howard Stern, Jeff Settleman, Timothy R. Wilson, Garret M. Hampton, Robert L. Yauch, Andrea Pirzkall, Lukas C. Amler

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors

    506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors oleh Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Jason Chesney, Mohammed Milhem, Kevin Harrington, Robert Coffin, Katy Tsai, Adel Samson, Bartosz Chmielowski, Ari VanderWalde, Andrea Pirzkall, Jiaxin Niu, Praveen Bommareddy, Georgia Beasley, Gino In, Terence Rhodes, Francesca Aroldi, Lavita Menezes, Tawnya Bowles, Hamid Emamekhoo, Scott Baum, Sophie Dalac-Rat, Katharina Kahler, Eva Muñoz

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors oleh Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif

    Diterbitkan 2018-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: